of the number of sites on the organs, when there was no evidence of incurable factors such as peritoneal dissemination, liver metastasis and widespread nodal involvement (Korenaga et al, 1988) . The lymph nodes in groups 1, 2 and 3 are referred to as n1, n2 and n3, respectively, based on lymph node metastasis. Lymph node dissection was classified as follows: D1, complete removal of group 1 lymph node alone; D2, complete removal of group 1 and 2 lymph nodes; and D3, complete removal of group 1, 2 and 3 lymph nodes. The pathological diagnosis and classification was according to the General Rules for the Gastric Cancer Study in Surgery and Pathology in Japan (Japanese Research Society for Gastric Cancer, 1981 Cancer, , 1993 . Curability A means no residual tumours with a high probability of cure, under the following conditions: no serosal invasion; n0 treated by D1, 2, 3 or n1 treated by D2 or 3; MO, peritoneal dissemination negative (P0), liver metastasis negative (H0); and the proximal and distal margins > 10 mm. Curability B means no residual tumours but not evaluable as Ôcurability AÕ, and curability C shows definite residual tumour. Tumour-advance stage was determined by the TNM classification of UICC (Sobin and Wittekind, 1997) .
Three patients (0.07%) died within the first 30 post-operative days. Of the remaining 424 patients, 173 are alive at the time of writing this report. Recurrence of the gastric cancer and death occurred in 173 patients, 55 died of another disease and 13 died of undetermined causes. Death owing to causes other than gastric cancer were considered as censored data in the statistical analysis.
p53 staining
Tissue sections were immunostained with a monoclonal antibody against p53 (PAb1801, Oncogene Science, USA) (Banks et al, 1986; Porter et al, 1992; Sarbia et al, 1994; Oiwa et al, 1995) . This antibody recognizes a denaturation-resistant epitope between amino acids 32 and 79 of both wild-type and mutant conformations. Xylene was used to remove paraffin from the 5-µm sections, then the sections were progressively hydrated in decreasing concentrations of ethanol. The slides were placed in a thermoresistant beaker filled with 0.1 M phosphate-buffered saline (PBS) (pH 7.4) and autoclaved at 121°C to allow the fixed embedded tissue antigen to react with the monoclonal antibody. The sections were then cooled down to room temperature for about 20 min and rinsed in PBS. These sections were then covered with normal rabbit serum for 15 min to reduce non-specific staining, then incubated with a 1:100 dilution of primary antibody at room temperature for 1 h. Next, the sections were washed with PBS, incubated with a 1:600 dilution of biotinylated goat anti-mouse IgG (Dako, Denmark) at room temperature for 30 min and then covered with a 1:1000 dilution of labelled streptavidin peroxidase (Dako) at room temperature for 30 min. The antibody was localized with 3,3′-diaminobenzidine tetrahydrochloride and 0.065% sodium azide was used to block endogenous peroxidase.
We stained both the deep periphery of the tumour and adjacent tumour-free tissue. A distinct nuclear immunoreaction for p53 was recorded as positive, and here the nuclear staining pattern was diffuse with little variation. When 10% of the cancer cells showed a positive nuclear staining, a positive-staining was defined (Kakeji et al, 1993) .
Post-operative chemotherapy
All of the patients with advanced stage of gastric cancer (t2Ðt4) were treated with post-operative chemotherapy (Sugimachi et al, 1997 ). An intravenous injection of 10 mg mitomycin C (Kyowa Hakko, Japan) was given on the day of operation, and fluorinated pyrimidine UFT (Taiho Pharmaceutical, Japan) orally in a daily dose of 400 mg was started 2 weeks after the operation and was continued for 1 year.
Statistical analysis
The BMDP Statistical Package program (BMDP; Los Angeles, CA, USA) for the IBM (Armonk, NY, USA) 3090 mainframe computer was used for all analyses (Dixon, 1988) . The BMDP P4F and P3S programs were used for the chi-squared test and the MannÐWhitney test to compare data from patients with p53-negative and p53-positive tumours. The BMDP P1L program was used to analyse survival rates by the KaplanÐMeier method, and the MantelÐCox method to test for equality of the survival curves. The BMDP P2L program was used for simultaneous multivariate adjustment of all covariates by the Cox regression analysis with the forward stepwise model (Cox, 1972) . The level of significance was P < 0.05.
RESULTS
The monoclonal antibody pAb1801 has been widely used for p53 protein expression in various cancer tissues. The positive rate of p53 expression in gastric cancer cells was 36.8% (165 out of 427). The staining of p53 was nuclear and p53 was never observed in the normal gastric mucosa examined in all 427 cases, as shown in Figure 1 . Table 1 shows clinicopathological data on 262 patients in whom there was no p53 expression and for 165 patients with p53 overexpression. In the p53-positive patients, the entire stomach was more likely to be involved, and the tumour was larger compared with p53-negative cases. There were no differences in tissue differentiation and growth patterns. Serosal invasion was more prominent, lymphatic and vascular involvement was more common and the rate of lymph node metastasis was higher in p53-positive tumours.
Clinicopathological factors
Surgical management was also compared between the groups (Table 2 ). There was no difference with regard to the extent of lymph node dissection. Because the entire stomach was more commonly involved, the rate of total gastrectomy was higher in the p53-positive patients. The rate of operative curability C (non-curative resection) was higher in p53-positive patients because of a more advanced stage of the tumour.
Survival rates
Post-operative survival curves for patients with p53-negative and p53-positive tumours are shown in Figure 2 . The non-gastric cancer deaths were considered as lost to follow-up, as of time of death, and data on survivors with a follow-up time shorter than 10 years were censored from analysis. The 5-year survival rate was 62.5% for p53-negative patients and 43.3% for p53-positive patients (P < 0.01).
Next, we determined survival rates for patients with p53-negative and p53-positive tumours for tumour size, serosal invasion, lymphatic and vascular invasion, lymph node metastasis and operative curability, which were identified as factors having a close relation with p53 expression as shown in Tables 1 and 2 . In the subgroups of tumour size over 5 cm, serosal invasion positive, lymphatic and vascular invasion positive and lymph node metastasis-positive tumours, and no residual tumours by curative resection (curability A and B), a significantly shorter survival time was noted in p53-positive patients compared with p53-negative patients (Table 3) . Survival curves for patients with p53-negative or p53-positive gastric cancers were determined for each nodenegative and node-positive group ( Figure 3A and B).
Recurrence pattern in curatively resected patients
Data from patients with p53-positive tumours and p53-negative tumours who underwent curative resection (curability A and B) were analysed for recurrence patterns (Table 4) . There was a recurrence in 39 out of 204 cases (19.1%) of p53-negative patients and in 29 out of 106 (27.4%) of p53-positive patients. In both groups, recurrence was noted in the peritoneum, distant organs and lymph nodes.
Multivariate analysis of p53 protein expression
Data from Cox regression analysis of all factors are listed in Table  1 , and revealed that lymph node metastasis, serosal invasion, liver metastasis, tumour size and peritoneal dissemination proved to be independent factors related to the prognosis of the patients but not for the p53 expression. Next, we examined the independence of p53 expression in the subgroup of lymph node metastasis-negative and -positive patients treated with curative resection (curability A and B). p53 expression proved to be a significant prognostic factor in patients with node-positive gastric cancer, as shown in Table 5 . Factors of age, sex, location of the tumour, histology, histological growth pattern and lymphatic involvement were not significant.
DISCUSSION
In this study, we made use of immunohistochemical staining to examine the relationship between p53 expression, clinicopathological factors and survival, in tissue samples from 427 patients resected because of gastric cancer. Alterations in the tumour-suppressor p53 gene play a role in the genesis of diverse types of human malignancies (Harris and Hollstein, 1993; Soussi et al, 1994; Chang et al, 1995) , and allelic losses and point mutations in the counterpart of the locus of the p53 gene in chromosome 17 are frequent. p53 mutation is a common event in gastric cancer, occurring from the early stage of progression with its specific mutation spectrum (Kim et al, 1991; Yokozaki et al, 1992; Uchino et al, 1993) . The mutated p53 gene loses function as a tumour suppressor and can act as a dominant oncogene (Levine et al, 1991) . Loss of p53 function accelerates the process of tumorigenesis and alters the phenotype of cancer cells and the response of cells to agents that damage DNA (Carson and Lois, 1995; Chang et al, 1995) . Mutant-type p53 proteins have a prolonged half-life, and are thus more likely than the wild-type protein to be detected using immunohistochemical assays (Finlay et al, 1988; Gannon et al, 1990; Levine et al, 1991) .
The antibody PAb1801, which we used, recognizes both the wild-type and mutant forms of p53 (Banks et al, 1986; Porter et al, 1992) . No reactivity was observed in any normal gastric mucosa adjacent to the tumour tissue and the normal protein has a very short half-life, suggesting that the immunoreactivity of p53 in the tumour tissue itself is likely to represent mutant forms of p53 and relates to a more malignant biological character. Conversely, 61.4% of the gastric cancers in this study were p53 negative. The tumours with immunohistochemically undetectable p53 could represent a decreased availability of the epitope of p53 protein as a result of fixation in paraffin, tumours with normal levels of wildtype p53, tumours with both alleles of the p53 gene deleted, or tumours expressing a mutant p53 protein not identified by the antibody used in this study (Gabbert et al, 1995) . 
Figure 2
Survival curves for patients with p53-negative or p53-positive gastric cancers. When the deaths were considered as gastric cancer-related, the patients with p53-positive tumours (n = 165) had a shorter survival time than did those with p53-negative tumours (n = 262) (P = 0.0002). Solid line, p53-negative patients; light line, p53-positive patients Figure 3 Survival curves for patients with p53-negative or p53-positive gastric cancers in each node-negative and node-positive group. (A) There was no difference between p53-negative (n = 120) and p53-positive patients (n = 49) for the node-negative group (P = 0.9583). (B) Survival time for p53-positive patients (n = 115) was shorter than for p53-negative patients (n = 138) in those in the node-positive group (P = 0.0060). Solid line, p53-negative patients; light line, p53-positive patients The p53 abnormal staining was reported to be related to the proliferating activity of cancer cells (Kakeji et al, 1993) , and aggressive behaviour of cancer cells for serosal invasion, lymph node metastasis of gastric cancer and a poorer prognosis ensued (Martin et al, 1992; Starzynska et al, 1992; Joypaul et al, 1994; Maehara et al, 1995; Mšnig et al, 1997) . Because vascular and lymphatic involvement are closely related to p53 expression, p53 expression was closely related to tumour invasion and metastasis and, in particular, proved to be a significant prognostic factor for node-positive cases. In cases of breast cancer, p53 expression was closely related to prognosis for node-negative cancers (Thor et al, 1992; Allred et al, 1993) . However, early stages of gastric cancer showed no lymph node metastasis, and the post-operative prognosis was improved in both p53-negative and -positive groups by the surgical treatment (Maehara et al, 1992b .
Other investigators reported that p53 overexpression is not related to the prognosis of human malignacies, including gastric cancer (Motojima et al, 1994; Schneider et al, 1994; Gabbert et al, 1995) . McLaren et al (1992) suggested that p53 was of considerable importance in the initiation of tumours in a wide variety of tissues, but the nature of the particular oncogene involved initially is probably of little significance once a tumour has developed. p53 protein expression could also be induced by a number of other factors, i.e. viral infection, oncogene overexpression and transcriptional activation, or mutations outside the conserved regions of p53 (Wynford-Thomas, 1992; Bell et al, 1993) . There are reports of a combined assessment of expressions of p53 and of other factors, for example, cyclin E and vascular endothelial growth factor as useful factors for evaluating tumour behaviour and the poor post-operative prognosis for subjects with various cancers (Kang et al, 1997; Furihata et al, 1998; Sakaguchi et al, 1998; Takahashi et al, 1998) . Therefore, these approaches may further the clinical usefulness of examining p53 expression.
The present findings show that p53 expression is closely related to tumour invasion and metastasis and a poorer prognosis in humans with gastric cancer. Because p53 is an integral part of anticancer-related DNA damage and apoptotic pathways (Caelles et al, 1994; Carson and Lois, 1995) , the clonal expansion of cells that acquire mutations in the p53 gene reveals resistance to cancer chemotherapy of solid tumours (Lowe et al, 1994) . Post-operative chemotherapy proved to be non-effective for p53-negative breast cancer, therefore accumulation of p53 protein can lead to enhanced chemoresistance (Koechli et al, 1994; Elledge et al, 1995) . Chin et al (1992) reported that the multidrug resistance gene could be activated during the tumour progression associated with mutations in p53. Almost all of our patients with advanced gastric cancer were prescribed post-operative chemotherapy, therefore the relation between p53 protein expression and the effect of post-operative chemotherapy could not be determined. An appropriate treatment for patients with gastric cancer with p53 expression has yet to be determined. 
